FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to novel azabicyclic compounds, represented by the given below general formula,or to their pharmaceutically acceptable salts. The said compounds demonstrate inhibition activity with respect to HSP90 and action inhibiting cellular proliferation. In formula (I) Xrepresents CH or N； one of X, Xand Xrepresents N, and the others represent CH； one or two of Y, Y, Yand Yrepresent C-R, one of the remaining ones represents CH or N and the remaining one represents CH； Rrepresents a monocyclic group optionally substituted 5- or 6-membered unsaturated heterocyclic group, which contains from 1 to 2 heteroatoms, selected from N, S and O, or an optionally substituted 9- or 10-membered bicyclic unsaturated heterocyclic group, which contains from 1 to 2 heteroatoms, selected from N, S and O, where the possible substituent is determined in the formula of the invention； Rrepresents a hydrogen atom, an optionally substituted with halogen atoms alkyl group, containing from 1 to 6 carbon atoms, or an alkenyl group, containing from 2 to 6 carbon atoms； and Rrepresents CO-R； Rare similar or different and represent a hydrogen atom, a halogen atom, a cyanogroup, an alkyl group, which contains from 1 to 6 carbon atoms, optionally substituted with a mono- or di(C-C-alkyl)aminogroup or a morpholine group, a cycloalkyl group, which contains from 3 to 7 carbon atoms, an alkenyl group, which contains from 2 to 6 carbon atoms, an alkoxygroup, which contains from 1 to 6 carbon atoms, a phenyl group, -N(R)(R), -S-Ror -CO-R； Rrepresents an aminogroup or mono- or di(C-Calkyl)aminogroup； R-Rhave values, given in the invention formula.EFFECT: invention relates to the pharmaceutical product, pharmaceutical composition and method of treating a cancer disease.11 cl, 3 tbl, 191 exИзобретение относится к новым азабициклическим соединениям, представленным приведенной ниже общей формулой (I), или к их фармацевтически приемлемым солям. Данные соединения
